Safety and tolerability evaluation after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus ranibizumab in New Zealand white rabbits

Table 2 ERG’s Maximum b-wave amplitude and semi saturation constant from the rabbits treated with PRO-169 and Ranibizumab intravitreal injections

	Experimental eye		Control eye		V_max ratio	δ Log σ
	V_max (µV)	Log σ (cd s/m²)	V_max (µV)	Log σ (cd s/m²)	V_max ratio	δ Log σ
PRO-169
1 month	128.747	− 2.626	154.359	− 2.253	0.879	− 0.373
2 months	276.490	− 2.313	266.438	− 2.353	1.031	0.040
3 months	286.428	− 2.473	238.032	− 2.756	1.050	0.094
Ranibizumab
1 month	135.376	− 2.177	136.858	− 2.218	1.007	0.041
2 months	268.382	− 2.468	299.659	− 2.332	0.907	− 0.136
3 months	241.647	− 2.696	229.543	− 2.760	1.118	0.064

Medium values. No significant differences between experimental (OD) and control eyes (OS) and between groups (injected eyes), in all comparisons, p > 0.05 (Mann–Whitney U test), n = 4 NWZ rabbit’s eyes per group

ISSN: 2056-9920